Study: Regeneron's protocol 0000-RA-1008, observing tocilizumab with methotrexate in adults with moderately to severely active rheumatoid arthritis after an inadequate response to an anti-TNF drug. 12
Design and measurements: The reproduced registry description is single-arm, open-label, and observational: participants were already scheduled to receive tocilizumab as standard care. Clinical and laboratory assessments accompanied the first three monthly intravenous infusions, approximately ten weeks, to examine safety and pharmacodynamic mechanisms. The registry lists 16 actual enrollees, versus 15 expected in the narrative; that enrollment count does not establish an analyzed outcome population. 12
What is established: The historical record is completed, last updated in October 2011. No numerical disease-activity, biomarker, or adverse-event result was verified. This was not a pivotal randomized approval trial or a comparison establishing superiority over another rheumatoid-arthritis treatment. 12